Go to content
Mar 20th 2010
Suomeksi
Text size
Home
Orion
Products and services
Research and development
News and media
Investors
Careers
Contacts
Home
/
Sitemap
Print
Sitemap
Orion
Orion in brief
Orion as a company
Orion Group operational structure
Best selling products
Business environment
Pharmaceutical markets
Diagnostic markets
Business Divisions
Proprietary Products
Specialty Products
Animal Health
Fermion
From a customer perspective
From a technology perspective
Fermion's history
Contacts
Orion Diagnostica
Line functions
Supply Chain
Sales and Marketing
Research and Development
Business Development and Support
Operational model
Quality – the cornerstone
Orion's Quality Policy
Safety above all
Strict criteria for raw materials
Customers
Strategy
Competitive product portfolio
Strengthening the market position in Europe
Efficient and competitive operations
Partnering / Licensing
Orion's partner management organisation
Partnering opportunities with Orion
Why partner with Orion?
Our partnership references
Corporate Governance
Group level
Business Divisions and line functions
Administration of legal entities
Internal control principles
Insiders in the Orion Group
Board of Directors
Board members
Board committees
Remuneration of the Board
Auditors
President and CEO
Executive Management Board
Introduction of the Executive Management Board
Remuneration of the Executive Management Board
Management remunerations
Articles of Association
General Meetings of the Shareholders
Risk Management
Strategic risks
Operational risks
Financial risks
General Meetings of the Shareholders
AGM 24 March 2010
AGM 23 March 2009
AGM 25 March 2008
AGM 2 April 2007
Corporate responsibility
Orion and the environment
Environmental reporting
Orion's collaboration with patient organisations in 2009
Orion's collaboration with patient organisations in 2008
History
Phases in 1940-1950's
Phases in 1960-1970's
Phases in 1980-1990's
Structural developments
Demerger on 30 June 2006
Phases of the diagnostics business
Values
Products and services
Human prescription medicines
Orion's portfolio of prescription medicines
Proprietary products portfolio
Products by therapeutic areas
CNS products
Stalevo® and Comtess®/Comtan®
Parkinson's Disease
Urological products
Enanton®, Vantas® and Kentera®
Disorders of the Prostate
Oncological products
Prostate Cancer
Critical Care products
Heart Failure
Simdax®
Dexmedetomidine
Products for Asthma and COPD
Asthma
Useful sources of information on pharmaceuticals and healthcare
Veterinary products
Aptus well-being range for pets
Active Pharmaceutical Ingredients
Diagnostic tests
Hygiene tests
Contract Manufacturing
Steriles
Solid Oral Dosages
Semi-Solid Forms
Liquids
Hormones
Cytotoxics
Contacts
Research and development
Proprietary Product Development
Non-clinical Research
Early development
Clinical Studies
Clinical Phase I
Clinical Phase II
Late development
Clinical Phase III
Biostatistics in Drug Development
Product Development
Drug registration and marketing authorisation
Drug Safety
Generic Development
Therapy areas of research
Central Nervous System medicines
Oncology and Critical Care
Inhaled medicinal products - the Easyhaler® platform
Generics
Animal Health
Achievements
R&D People
Contact information
R&D Themes
R&D collaboration
The Best R&D in the World
R&D Vocabulary
News and media
Subscribe for publications
Stock exchange releases
Stock exchange announcements
Press releases
Annual Reports
Financial Reviews
2008
2007
2006
Presentations
Magazines
Other publications
Media Bank
Media contacts
Investors
Orion as an investment case
CEO's review
2008
2007
Operational enviroment
Market review on human pharmaceuticals
Strategy
R&D in brief
Pharmaceutical R&D pipeline
Orion´s proprietary drugs
Outlook
Basis for outlook
2009
2008
2007
2006
Financial targets
Dividends
Consensus estimates
Analysts
Corporate Governance
Risk management
Messages to shareholders
Calendar
2009
2008
2007
2006
Financials
Financial reporting
Financial targets
Outlook
Credit programmes
Annual Reports
Interim Reports
Listing Particulars
Accounting policies
Calculation of key figures
Shares
Basic share information
Share capital
Share-related key figures
Share buy-backs
Sharemonitor
Share price lookup
Total Return Calculator
Dividends
Shareholder base
Major shareholders by shares
Major shareholders by votes
Ownership structure
Type of shareholder in graphs
Notification threshold
Insider register
Shareholder register
Investor contacts
Changes in contact details
Silent period
Careers
Vacancies
Open vacancies
Open application
For students
Orion as a workplace
Key figures on Orion employees
Growth and development
Healthy and happy personnel
Builders of well-being
Contacts
Contact persons
Pharmaceutical manufacturing
Pharmaceutical Sales
Sales companies, Human Pharmaceuticals
Animal Health
Fermion Oy
Orion Diagnostica Oy
Tuohilampi
Invoicing addresses
Exchange 0104261, Company code 1999212-6
© Copyright Orion Oyj, Orionintie 1A, 02200 Espoo, PO Box 65, FI-02101 Espoo, Finland
About this website
Disclaimer
Sitemap
Feedback form
